The genetics of Alzheimer Disease - like most degenerative neurological disorders - is a complex interaction of genetic and epigenetic (which are external, influencing agents which may impact an individual's genes, without affecting the underlying genome - tobacco smoke, air pollution, radiation, drugs, industrial chemicals & pesticides, starvation, and simple aging are known examples ). I have heard genetic/epigenetic influence described as a board of flip-switches (which represent individual genetic markers/sequences), where you will not develop a disease/disorder unless an extraordinarily complex combination of "on-off " switches are coordinated & realized on or off.
Be aware that the National Library of Medicine ("PubMed" - NCBI) maintains the Online Mendelian Inheritance in Man ([Login to see the link]),which is a searchable "catalog of human genes and genetic disorders and traits, with particular focus on the molecular relationship between genetic variation and phenotypic expression." You can search and download by disease/disorder, symbol, phenotype, etc., and simply searching on "alzheimer" results in 405 references, including primary genes and contributory genes and processes.
One interesting example of pursuing the genetic influences of Alzheimer's Disease is to focus on the discovery of the gene responsible for the "beta-amyloid protein" in 1984 (which is identified by the symbol APP, cytogenic location 21q21.3, and genomic coordinates 21:25,880,550-26,171,128). This is responsible for the formation of the twisted plaque core that characterizes what we know as primary "Alzheimer' Disease 1, familial" (and interestingly enough, this amino acid composition, molecular mass, etc. is "nearly identical" to what is found in Down's Syndrome). You can find this presentation here: [Login to see the link]
Finally, I like this citation, specifically related to "early-onset" Alzheimer's Disease, but a good review of the core science.
Cacace, R., Sleegers, K., Van Broeckhoven, C. Molecular genetics of early-onset Alzheimer's disease revisited. Alzheimer's & Dementia Volume 12, Issue 6, June 2016, Pages 733-748, [Login to see the link].
Abstract
As the discovery of the Alzheimer's disease (AD) genes, APP, PSEN1, and PSEN2, in families with autosomal dominant early-onset AD (EOAD), gene discovery in familial EOAD came more or less to a standstill. Only 5% of EOAD patients are carrying a pathogenic mutation in one of the AD genes or a apolipoprotein E (APOE) risk allele ε4, most of EOAD patients remain unexplained. Here, we aimed at summarizing the current knowledge of EOAD genetics and its role in ongoing approaches to understand the biology of AD and disease symptomatology as well as developing new therapeutics. Next, we explored the possible molecular mechanisms that might underlie the missing genetic etiology of EOAD and discussed how the use of massive parallel sequencing technologies triggered novel gene discoveries. To conclude, we commented on the relevance of reinvestigating EOAD patients as a means to explore potential new avenues for translational research and therapeutic discoveries.
[Login to see the link]